



## Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 6, 2025

BURLINGAME, Calif.--(BUSINESS WIRE)--Feb. 6, 2025-- Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a podium presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 2:00 p.m. Eastern Time. The conference will be held in a virtual format.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at <https://investor.inva.com/presentations-events>. The webcast will be available for replay for 90 days following the event.

### About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of *Acinetobacter baumannii-calcoaceticus* complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250206874486/en/): <https://www.businesswire.com/news/home/20250206874486/en/>

Innoviva, Inc.  
David Patti  
Corporate Communications  
(908) 421-5971  
[david.patti@inva.com](mailto:david.patti@inva.com)

Investors and Media:  
Argot Partners  
(212) 600-1902  
[innoviva@argotpartners.com](mailto:innoviva@argotpartners.com)

Source: Innoviva, Inc.